MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
MacroGenics Financial Update: MacroGenics has entered a royalty purchase agreement with Sagard Healthcare Partners, receiving a $70 million upfront payment which extends its cash runway through the first half of 2027, supporting ongoing clinical programs.
ZYNYZ Overview: ZYNYZ (retifanlimab-dlwr), a PD-1 inhibitor developed by MacroGenics and marketed by Incyte, is indicated for certain cancer treatments in adults, with continued approval contingent on further clinical trials.
Trade with 70% Backtested Accuracy
Analyst Views on MGNX
About MGNX
About the author
Incyte's Cancer Therapy Zynyz Receives EMA Endorsement for New Indication
- New Indication Endorsement: Incyte's Zynyz (retifanlimab), marketed in collaboration with MacroGenics, has received endorsement from the European Medicines Agency (EMA) expert panel as a first-line treatment option for certain adults with squamous cell carcinoma, marking a significant advancement in cancer therapy.
- Innovative Treatment Combination: The therapy is recommended in combination with platinum-based chemotherapy for squamous cell carcinoma of the anal canal (SCAC), which accounts for 85% of anal cancer cases; despite being rare, its incidence is rising by approximately 3% annually, indicating potential market demand.
- Current Market Status: Zynyz is already available in the EU as a single-agent first-line treatment for certain cases of Merkel cell carcinoma, and this new indication will further expand its market application, enhancing the company's competitiveness in cancer treatment.
- Approval Process Ahead: The EMA's Committee for Medicinal Products for Human Use (CHMP) recommendation will be reviewed by the European Commission (EC) for final approval, which, if granted, could provide Incyte with a new revenue stream and strengthen its market position.
After-Hours Movers: MGNX, SLS, KRMD, HYPR, WVE Experience Significant Changes After Q3 Reports
MacroGenics Earnings Report: MacroGenics, Inc. saw a 10.2% increase in after-hours trading, reporting a third-quarter net income of $16.8 million, down from $56.3 million year-over-year, with revenue falling to $72.8 million.
SELLAS Life Sciences Update: SELLAS Life Sciences Group, Inc. rose 9.4% after narrowing its quarterly net loss to $6.8 million, with cash and equivalents reported at approximately $44.3 million as of September 30, 2025.
KORU Medical Systems Performance: KORU Medical Systems, Inc. gained 8.47% after reporting a narrower net loss of $0.8 million and a 27.2% revenue increase to $10.4 million, while raising its full-year revenue guidance.
Wave Life Sciences Results: Wave Life Sciences Ltd. increased by 5.68% after reporting a third-quarter net loss of $53.9 million, an improvement from the previous year, with revenue of $7.6 million.
MacroGenics Revenue Doubles in Q2
Financial Performance: MacroGenics reported Q2 2025 GAAP revenue of $22.2 million, significantly below the $31.7 million analyst estimate, with a loss per share of $(0.57), missing expectations as well. The company highlighted lower operating costs but faced challenges due to the absence of product sales after exiting its previous marketed product.
Strategic Focus and Pipeline: The company is shifting its focus to research-stage pipeline candidates, emphasizing partnerships and cost management while maintaining sufficient funds through mid-2027. Key upcoming milestones include clinical results for its lead candidate lorigerlimab and potential regulatory approvals for collaborations that could yield significant payments.
OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates
Quarterly Performance: OrganiGram reported a quarterly loss of $0.03 per share, missing the Zacks Consensus Estimate of a loss of $0.01, while revenues reached $51.16 million, exceeding expectations and showing significant year-over-year growth.
Market Outlook: The company's stock has underperformed compared to the S&P 500 this year, with a mixed earnings estimate revision trend leading to a Zacks Rank #3 (Hold), indicating expected performance in line with the market moving forward.
MacroGenics signs financial deal with Sagard for retifanlimab
Financial Agreement with Sagard: MacroGenics has entered into a financial agreement with Sagard, receiving an upfront payment of $70 million for royalty rights related to their PD-1 inhibitor, retifanlimab, while retaining certain economic interests and continuing to assist in manufacturing.
Future Royalties and Financial Outlook: Once Sagard collects $140 million in royalties, MacroGenics will regain the right to future royalties, extending the company's financial runway into the first half of 2027.
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
Incyte's Cancer Therapy Zynyz Receives EMA Endorsement for New Indication
- New Indication Endorsement: Incyte's Zynyz (retifanlimab), marketed in collaboration with MacroGenics, has received endorsement from the European Medicines Agency (EMA) expert panel as a first-line treatment option for certain adults with squamous cell carcinoma, marking a significant advancement in cancer therapy.
- Innovative Treatment Combination: The therapy is recommended in combination with platinum-based chemotherapy for squamous cell carcinoma of the anal canal (SCAC), which accounts for 85% of anal cancer cases; despite being rare, its incidence is rising by approximately 3% annually, indicating potential market demand.
- Current Market Status: Zynyz is already available in the EU as a single-agent first-line treatment for certain cases of Merkel cell carcinoma, and this new indication will further expand its market application, enhancing the company's competitiveness in cancer treatment.
- Approval Process Ahead: The EMA's Committee for Medicinal Products for Human Use (CHMP) recommendation will be reviewed by the European Commission (EC) for final approval, which, if granted, could provide Incyte with a new revenue stream and strengthen its market position.
After-Hours Movers: MGNX, SLS, KRMD, HYPR, WVE Experience Significant Changes After Q3 Reports
MacroGenics Earnings Report: MacroGenics, Inc. saw a 10.2% increase in after-hours trading, reporting a third-quarter net income of $16.8 million, down from $56.3 million year-over-year, with revenue falling to $72.8 million.
SELLAS Life Sciences Update: SELLAS Life Sciences Group, Inc. rose 9.4% after narrowing its quarterly net loss to $6.8 million, with cash and equivalents reported at approximately $44.3 million as of September 30, 2025.
KORU Medical Systems Performance: KORU Medical Systems, Inc. gained 8.47% after reporting a narrower net loss of $0.8 million and a 27.2% revenue increase to $10.4 million, while raising its full-year revenue guidance.
Wave Life Sciences Results: Wave Life Sciences Ltd. increased by 5.68% after reporting a third-quarter net loss of $53.9 million, an improvement from the previous year, with revenue of $7.6 million.
MacroGenics Revenue Doubles in Q2
Financial Performance: MacroGenics reported Q2 2025 GAAP revenue of $22.2 million, significantly below the $31.7 million analyst estimate, with a loss per share of $(0.57), missing expectations as well. The company highlighted lower operating costs but faced challenges due to the absence of product sales after exiting its previous marketed product.
Strategic Focus and Pipeline: The company is shifting its focus to research-stage pipeline candidates, emphasizing partnerships and cost management while maintaining sufficient funds through mid-2027. Key upcoming milestones include clinical results for its lead candidate lorigerlimab and potential regulatory approvals for collaborations that could yield significant payments.
OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates
Quarterly Performance: OrganiGram reported a quarterly loss of $0.03 per share, missing the Zacks Consensus Estimate of a loss of $0.01, while revenues reached $51.16 million, exceeding expectations and showing significant year-over-year growth.
Market Outlook: The company's stock has underperformed compared to the S&P 500 this year, with a mixed earnings estimate revision trend leading to a Zacks Rank #3 (Hold), indicating expected performance in line with the market moving forward.
MacroGenics signs financial deal with Sagard for retifanlimab
Financial Agreement with Sagard: MacroGenics has entered into a financial agreement with Sagard, receiving an upfront payment of $70 million for royalty rights related to their PD-1 inhibitor, retifanlimab, while retaining certain economic interests and continuing to assist in manufacturing.
Future Royalties and Financial Outlook: Once Sagard collects $140 million in royalties, MacroGenics will regain the right to future royalties, extending the company's financial runway into the first half of 2027.
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
